Market Cap | 27.07K | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
Income | -12.87M | Forward P/E | - | EPS next Y | - | 50D Avg Chg | -99.00% |
Sales | 128.6k | PEG | - | EPS past 5Y | - | 200D Avg Chg | -99.00% |
Dividend | N/A | Price/Book | 0.00 | EPS next 5Y | - | 52W High Chg | -100.00% |
Recommedations | - | Quick Ratio | 0.00 | Shares Outstanding | 270.72M | 52W Low Chg | - |
Insider Own | 39.00% | ROA | -293.37% | Shares Float | 149.22M | Beta | 1.38 |
Inst Own | 4.43% | ROE | - | Shares Shorted/Prior | -/- | Price | 0.00010 |
Gross Margin | 86.92% | Profit Margin | - | Avg. Volume | 6,618 | Target Price | - |
Oper. Margin | -4,971.76% | Earnings Date | Aug 20 | Volume | 635 | Change | 0.00% |
Parallax Health Sciences, Inc. builds and expands an integrated digital healthcare network with products and services that provide remote communication, diagnosis, treatment, and monitoring of patients. The company offers remote healthcare products, including patent pending software and mobile apps, and other services, as well as electronic kits and devices from third-party licensed platforms that are designated towards a patient's primary health concern, such as diabetes, blood pressure, cardiovascular, general monitoring, etc.; and audio and video options that interface with the patient's healthcare providers. It also provides prescription medication dosage monitoring services; and behavioral health products comprising REBOOT, a proprietary behavioral health technology for an individual or an organization to transform the cost of treating and managing chronic illnesses that include pulmonary-COPD-asthma, diabetes, and cardiovascular diseases by effecting the modification of behavior in patients being treated for these chronic diseases. In addition, the company offers diagnostics products, which comprise Target System, a proprietary POC diagnostic immunoassay testing platform; and test cartridges for the areas of infectious diseases, cardiac markers, drugs of abuse, and various other medical conditions, as well as VT-1000 desktop analyzers, target antigen detection systems, and other products. Further, it provides SPARKS Mobile, a target system hand-held analyzer; COMPASS for behavioral modification; Fotodigm platform for remote patient monitoring, telehealth, and POC diagnostic testing services; and Intrinsic Code technology for actionable insights to behavior modification. The company was formerly known as Endeavor Power Corporation and changed its name to Parallax Health Sciences, Inc. in January 2014. Parallax Health Sciences, Inc. was founded in 2005 and is headquartered in Santa Monica, California.